With 2027 fast approaching, I've been thinking about which ASX shares I'd like to own next year.
There are plenty of opportunities out there, but the ten shares below are among my favourites. Here's why I think they could be great investments in 2027 and beyond.
The first ASX share I'd buy is gaming technology company Aristocrat Leisure.
I'm a big fan of its ability to develop popular gaming content and increase its presence on casino floors. In FY 2026, Aristocrat added approximately 6,500 machines to its North American installed base.
This creates additional recurring revenue and, combined with its strong pipeline of new games, could support another year of attractive earnings growth.
Another ASX share I'd buy is Breville. Its premium coffee machines continue to sell well despite challenging consumer conditions.
I'm especially positive about its international expansion, including its recent entry into China. If Breville can replicate its success in established markets, I believe its earnings could be substantially higher in five years.
Cochlear has had a difficult year, but I think its long-term prospects remain attractive.
Its new Nucleus Nexa hearing implant system could support a recovery in sales growth, while management has reaffirmed its FY 2027 profit guidance.
With an enormous market opportunity and a strong competitive position, I'd be happy to buy shares while sentiment remains weak.
Industrial property giant Goodman is another favourite of mine. Its growing data centre business offers significant opportunities as demand for artificial intelligence infrastructure increases.
Importantly, Goodman has already secured 3.6 gigawatts of power, giving it a major advantage in developing new facilities.
I believe converting this capacity into completed projects could generate substantial earnings growth over the coming years.
I'm also bullish on investment platform provider HUB24. This ASX share continues taking market share from established platforms, attracting $4 billion in net inflows during the September quarter.
And with still a huge market share up for grabs, I think HUB24 is well-positioned to deliver strong earnings growth in 2027 and beyond.
Another ASX share I'd buy is Macquarie. Its half-year profit recently jumped 50%, supported by strong performances across several businesses.
While some of this growth won't necessarily repeat, I believe its global asset management and commodities operations offer attractive opportunities that Australia's traditional banks cannot match.
REA Group is another ASX share I'd happily own in 2027. Its first-quarter revenue increased 11% despite national property listings declining 2%.
This highlights its impressive pricing power, which I believe will continue supporting earnings growth even when Australia's property market is subdued.
ResMed remains one of my favourite long-term ASX share investments.
The sleep disorder treatment giant has an enormous opportunity to expand its patient base, while its growing mask and accessories business provides recurring revenue.
Combined with improving margins, I believe this could support strong earnings growth for many years.
TechnologyOne continues to impress me. The enterprise software provider's annual recurring revenue (ARR) increased 18% to $652 million in FY 2026, and management is targeting more than $1 billion by FY 2030.
With demand for its cloud software remaining strong, I think TechnologyOne has a good chance of achieving this target.
A final ASX share I'd buy is Xero. Its shares have fallen heavily in 2026, but I'm positive about its longer-term growth opportunities.
The Melio acquisition could significantly strengthen its position in the US small business market, while improving profitability should support earnings growth.
If management delivers, I think Xero shares could recover strongly in 2027.
The post 10 top ASX shares I'd buy in 2027 appeared first on The Motley Fool Australia.
Motley Fool contributor James Mickleboro has positions in Cochlear, Goodman Group, REA Group, ResMed, Technology One, and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear, Goodman Group, Macquarie Group, ResMed, and Xero. The Motley Fool Australia has positions in and has recommended Goodman Group, ResMed, and Xero. The Motley Fool Australia has recommended Cochlear, Hub24, and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026